ES2145748T3 - Composicion liofilizada que contiene s(+)-4,4'-(1-metil-1,2-etanodiil)-bis(2,6-piperazinodiona). - Google Patents

Composicion liofilizada que contiene s(+)-4,4'-(1-metil-1,2-etanodiil)-bis(2,6-piperazinodiona).

Info

Publication number
ES2145748T3
ES2145748T3 ES92921457T ES92921457T ES2145748T3 ES 2145748 T3 ES2145748 T3 ES 2145748T3 ES 92921457 T ES92921457 T ES 92921457T ES 92921457 T ES92921457 T ES 92921457T ES 2145748 T3 ES2145748 T3 ES 2145748T3
Authority
ES
Spain
Prior art keywords
icrf
piperazinodiona
ethanodiyl
bis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92921457T
Other languages
English (en)
Inventor
Josephus Johannes Mar Holthuis
Alwinus Antonius Voetman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10703550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145748(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2145748T3 publication Critical patent/ES2145748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA PREPARACION LIOFILIZADA ESTABLE DE ICRF QUE LA PASTILLA DE ICRF CIVOS DE LUZ, TIENE UN CONTENIDO DE HUMEDAD DE NO MAS DE UN 2%, Y SE OBTIENE MEDIANTE UN PROCESO DE LIOFILIZACION, USANDO UNA SOLUCION DE INICIACION DE UNA SAL ACIDA TERAPEUTICAMENTE ACEPTABLE, DE ICRF 187, TENIENDO UNA CONCENTRACION DE HASTA 25 MG/ML, Y EN LA QUE LA FASE DE SECADO PRIMARIA TARDA AL MENOS 30 HORAS, PREFERENTEMENTE AL MENOS 40 HORAS, Y/O USA UNA TEMPERATURA DE SECADO PRIMARIA ENTRE 30
ES92921457T 1991-10-25 1992-10-22 Composicion liofilizada que contiene s(+)-4,4'-(1-metil-1,2-etanodiil)-bis(2,6-piperazinodiona). Expired - Lifetime ES2145748T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919122720A GB9122720D0 (en) 1991-10-25 1991-10-25 (s)(+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)formulations and their preparation

Publications (1)

Publication Number Publication Date
ES2145748T3 true ES2145748T3 (es) 2000-07-16

Family

ID=10703550

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92921457T Expired - Lifetime ES2145748T3 (es) 1991-10-25 1992-10-22 Composicion liofilizada que contiene s(+)-4,4'-(1-metil-1,2-etanodiil)-bis(2,6-piperazinodiona).

Country Status (11)

Country Link
EP (1) EP0619735B1 (es)
AT (1) ATE193205T1 (es)
AU (1) AU2791292A (es)
DE (1) DE69231098T2 (es)
DK (1) DK0619735T3 (es)
ES (1) ES2145748T3 (es)
GB (1) GB9122720D0 (es)
GR (1) GR3034135T3 (es)
MX (1) MX9206139A (es)
PT (1) PT101007B (es)
WO (1) WO1993007873A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265385B1 (en) * 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
CA2367240C (en) * 1999-03-12 2010-11-16 Clinigen Group Plc Treatment of accidental extravasation of anthracyclines
WO2007062076A2 (en) * 2005-11-23 2007-05-31 Novartis Ag Dexrazoxane formulations and methods
CN114306251B (zh) * 2021-12-22 2023-08-11 乐普药业股份有限公司 一种含有右雷佐生的冻干制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
US4963551A (en) * 1987-12-21 1990-10-16 Erbamont Inc. Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof

Also Published As

Publication number Publication date
DE69231098T2 (de) 2000-09-14
EP0619735A1 (en) 1994-10-19
MX9206139A (es) 1993-07-01
WO1993007873A1 (en) 1993-04-29
GB9122720D0 (en) 1991-12-11
ATE193205T1 (de) 2000-06-15
GR3034135T3 (en) 2000-11-30
DK0619735T3 (da) 2000-12-04
AU2791292A (en) 1993-05-21
DE69231098D1 (de) 2000-06-29
EP0619735B1 (en) 2000-05-24
PT101007B (pt) 1999-07-30
PT101007A (pt) 1994-01-31

Similar Documents

Publication Publication Date Title
FI61807B (fi) Foerfarande foer stabilisering av meningokockpolysackarid
KR930007453A (ko) 동결건조 이포스파미드 조성물
KR920019371A (ko) 안정화된 인자 ⅷ 제제
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
US4079126A (en) Method of preparing a component consisting of sugar, lipid and protein derived from Pseudomonas aeruginosa which possess anti-tumor and interferon inducing properties
GR3006172T3 (es)
ATE159250T1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
ATE148165T1 (de) Stabilisierung von hochgereinigten proteinen
KR870700599A (ko) 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
GB1446284A (en) Neurotoxin
FI103408B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsolijohdannaisten valmistamiseksi
KR900003205A (ko) 제약 화합물
DE69111205D1 (de) Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
KR910000158A (ko) 의약용 화합물 및 그것의 사용방법
KR910000146A (ko) 동결- 건조된 조성물 및 그 제조 방법
DK0619735T3 (da) Lyofiliseret præparat, der indeholder S(+)-4,4'-(1-methyl-1,2ethandijyl)-bis(2,6-piperazindion)
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
PT92047A (pt) Processo para a preparacao de derivados de nitroxialquilaminas com a funcao amida, de compostos intermediarios e de composicoes farmaceuticas que as contem
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
JPS6416799A (en) H-pth (1-34) composition and its preparation
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619735

Country of ref document: ES